MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The analyst cut her price target on MRNA to $51 from $99 ... which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison’s Statement on Potential Cancer ...

Martin shared that strategists have been putting out their target price for the S&P 500 ... If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 ...

Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.

The analyst cut her price target on MRNA to $51 from $99 ... But she does not expect the jab, which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison's ...